Cargando…
Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy
INTRODUCTION: The clinical assessment of the myocardial damage caused by anthracyclin (ANT)-therapy is difficult. Therefore a study was performed to evaluate non-invasive markers of anthracyclin-induced cardiac effects, with emphasis on course-to-course variation. METHODS: Eligible for study partici...
Autores principales: | Broeyer, F. J. F., Osanto, S., Ritsema van Eck, H. J., van Steijn, A. Q. M. J., Ballieux, B. E. P. B., Schoemaker, R. C., Cohen, A. F., Burggraaf, J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515587/ https://www.ncbi.nlm.nih.gov/pubmed/18343950 http://dx.doi.org/10.1007/s00432-008-0372-8 |
Ejemplares similares
-
Anthracycline Chemotherapy and Cardiotoxicity
por: McGowan, John V, et al.
Publicado: (2017) -
Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
por: Briasoulis, Alexandros, et al.
Publicado: (2022) -
Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors
por: Willemse, P M, et al.
Publicado: (2013) -
Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors
por: Willemse, P M, et al.
Publicado: (2013) -
Cardiotoxicity of Anthracyclines
por: Cardinale, Daniela, et al.
Publicado: (2020)